THERATARGET, INC.
Biotech · Private
Genetically engineered silk-elastin-like protein (SELP-815K) liquid embolic agent that converts to hydrogel in-situ for transcatheter arterial chemoembolization (TACE) in liver cancer treatment
theratarget.com →- Grants
- $4.3M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer | $492,378 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma | $1,495,828 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma | $400,462 | |
| Federal grant | Department of Health and Human Services · Phase I · Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms | $250,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase II · In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma | $694,475 | |
| Federal grant | Department of Health and Human Services · Phase II · In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma | $399,441 | |
| Federal grant | Department of Health and Human Services · Phase I · Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms | $150,000 | |
| Federal grant | Department of Health and Human Services · Phase II · In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma | $1,450 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1311 | Riptide Bioscience, Inc. | — | — |
| 1312 | TING THERAPEUTICS LLC | — | — |
| 1313 | Kodikaz Therapeutic Solutions, Inc. | — | — |
| 1314 | THERATARGET, INC. | — | — |
| 1315 | OAKGROVE BIO LLC | — | — |
| 1316 | MEDVAS CONCEPTS, LLC | — | — |
| 1317 | CADRE BIOSCIENCE, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.